Full Press Release Details
Doses First Patient in Global Phase II Liver Cancer Trial for CF102
follows successful Phase I/II study which met all study endpoints
granted Orphan Drug Status for this indication by the FDA
Industry Analysts predict that the global market for liver cancer is projected to exceed $2B by 2015
TIKVA, Israel, December 22, 2014 -- Can-Fite BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI), a biotechnology company advancing
a pipeline of proprietary small molecule drugs that address cancer and inflammatory diseases, today announced that it has dosed
the first patient in a Phase II trial for the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.
Phase II randomized, double-blind, placebo controlled trial is to be conducted in the U.S., Europe and Israel with an estimated
78 patients to be enrolled. CF 102 is being evaluated for efficacy and safety as a second-line treatment for advanced HCC
in subjects with Child-Pugh B who failed Nexavar as a first line treatment. The first patient was dosed at the study's Israeli
site, the Rabin Medical Center. The primary endpoint of the study is overall patient survival.
II study follows favorable results in Can-Fite's Phase I/II study, which was an open-label, dose-escalation study that evaluated
the safety, tolerability, pharmacokinetics, and pharmacodynamics of the orally administered CF102 in patients with advanced primary
HCC. Data from that trial showed prolonged survival, stable disease in some patients, and regression of skin tumor metastases,
as well as a favorable safety profile and lack of hepatotoxicity.
believe we have reached an important milestone in this trial by commencing the dosing of patients with CF102. We are proud to
be working with some of the top medical institutions in the world on this trial, including Tufts Medical School in the U.S. and
the Rabin Medical Center in Israel. As we continue to screen for new patients, we look forward to advancing the trial towards
full enrollment," stated Can-Fite CEO Dr. Pnina Fishman.
the Phase II data show results similar to our Phase I/II study, we believe this would indicate that CF102 may offer clear benefits
and a prolonged life for liver cancer patients," Dr. Fishman added.
Food and Drug Administration has granted Orphan Drug Status to Can-Fite's CF 102 for this indication. Israel's Ministry
of Health has also approved CF102 for Compassionate Use in liver cancer. Global Industry Analysts predicts that the global market
for liver cancer is projected to exceed $2B by 2015.
a small orally bioavailable drug that binds with high affinity and selectivity to the A3 adenosine receptor (A3AR). A3AR is highly
expressed in tumor cells whereas low expression is found in normal cells. This differential effect accounts for the excellent
safety profile of the drug. In Can-Fite's pre-clinical and clinical studies, CF102 has demonstrated a robust anti-tumor
effect via deregulation of the Wnt signaling pathway, resulting in apoptosis of liver cancer cells. CF102 is in Phase II clinical
trials for the treatment of liver cancer in the U.S., Israel, and Europe. The U.S. Food and Drug Administration has agreed with
Can-Fite's Phase II study protocol and had previously granted Can-Fite Orphan Drug Designation for CF102 in the treatment
of hepatocellular carcinoma, the most common form of liver cancer.
Can-Fite BioPharma Ltd.
BioPharma Ltd. (NYSE MKT: CANF) (TASE: CFBI) is an advanced clinical stage drug development company with a platform technology
that is designed to address multi-billion dollar markets in the treatment of cancer and inflammatory diseases. The Company's
CF101 is in Phase II/III trials for the treatment of psoriasis and the Company is preparing for a Phase III CF101 trial for rheumatoid
arthritis. Can-Fite's liver cancer drug CF102 is commencing Phase II trials and has been granted Orphan Drug Designation
by the U.S. Food and Drug Administration. CF102 has also shown proof of concept to potentially treat other cancers including colon,
prostate, and melanoma. These drugs have an excellent safety profile with experience in over 1,200 patients in clinical studies
to date. For more information, please visit: www.can-fite.com
release may contain forward-looking statements, about Can-Fite's expectations, beliefs or intentions regarding, among other things,
its product development efforts, business, financial condition, results of operations, strategies or prospects. In addition, from
time to time, Can-Fite or its representatives have made or may make forward-looking statements, orally or in writing. Forward-looking
statements can be identified by the use of forward-looking words such as "believe," "expect," "intend,"
"plan," "may," "should" or "anticipate" or their negatives or other variations of these
words or other comparable words or by the fact that these statements do not relate strictly to historical or current matters.
These forward-looking statements may be included in, but are not limited to, various filings made by Can-Fite with the U.S. Securities
and Exchange Commission, press releases or oral statements made by or with the approval of one of Can-Fite's authorized executive
officers. Forward-looking statements relate to anticipated or expected events, activities, trends or results as of the date they
are made. Because forward-looking statements relate to matters that have not yet occurred, these statements are inherently subject
to risks and uncertainties that could cause Can-Fite's actual results to differ materially from any future results expressed or
implied by the forward-looking statements. Many factors could cause Can-Fite's actual activities or results to differ materially
from the activities and results anticipated in such forward-looking statements, including, but not limited to, the factors summarized
in Can-Fite's filings with the SEC and in its periodic filings with the TASE. In addition, Can-Fite operates in an industry sector
where securities values are highly volatile and may be influenced by economic and other factors beyond its control. Can-Fite does
not undertake any obligation to publicly update these forward-looking statements, whether as a result of new information, future
events or otherwise.